NDC codes

FDA NDC Directory
Product NDC (as listed)69097-639Labeler and product segments. Claims need a package NDC.
Product NDC at billing width69097-0639Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
69097-639-03690970639036909706390360 CAPSULE in 1 BOTTLE (69097-639-03)Marketed from Apr 2, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Nintedanib
Generic name (nonproprietary)
nintedanib
Active ingredients
Nintedanib esylate — 150 mg/1
Dosage form
Capsule
Route
Oral
Labeler
Cipla USA Inc.NDC labeler code 69097
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 212609
Marketing start
Listing expires
Other FDA classes
Protein Kinase Inhibitors (Mechanism)
Identifiers
Product ID 69097-639_128511d3-f076-4a68-993b-53ad52233ee2SPL ID 128511d3-f076-4a68-993b-53ad52233ee2SPL set ID 4d017c42-a823-452d-bc6f-0491dd9823e3RxCUI 1592742, 1592750UNII 42F62RTZ4G
Pharmacologic class
Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469097063903 followed by a unit qualifier and the quantity

Package 69097-0639-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

Nintedanib is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF). ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). ( 1.3 ) 1.1 Idiopathic Pulmonary Fibrosis Nintedanib capsule is indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Nintedanib capsule is indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a p…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 69097-639

What is NDC 69097-639?
69097-639 is the product NDC for Nintedanib, Nintedanib esylate 150 mg/1 capsule, listed with the FDA by Cipla USA Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?
Nintedanib.
What is the active ingredient?
Nintedanib esylate.
Who is the labeler?
Cipla USA Inc., NDC labeler code 69097. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Nintedanib?
17 other product NDCs are listed under this name. See all Nintedanib NDCs.
Is there a related HCPCS / J-code?
Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Nintedanib NDCs
ProductStrengthForm · routeLabelerProduct NDCPackage NDCs (11-digit)
nintedanibNintedanib esylate 100 mg/1CapsuleOralAvKARE73190-09673190-0096-60
nintedanibNintedanib esylate 150 mg/1CapsuleOralAvKARE73190-09773190-0097-60
nintedanibNintedanib esylate 150 mg/1CapsuleOralEPIC PHARMA LLC42806-56842806-0568-60
nintedanibNintedanib esylate 100 mg/1CapsuleOralEPIC PHARMA LLC42806-56942806-0569-60
nintedanibNintedanib esylate 100 mg/1CapsuleOralGlenmark Pharmaceuticals Inc., USA68462-80268462-0802-60
nintedanibNintedanib esylate 150 mg/1CapsuleOralGlenmark Pharmaceuticals Inc., USA68462-80368462-0803-60
NintedanibNintedanib esylate 100 mg/1CapsuleOralEdenbridge Pharmaceuticals LLC.42799-97242799-0972-01
NintedanibNintedanib esylate 150 mg/1CapsuleOralEdenbridge Pharmaceuticals LLC.42799-97342799-0973-01
nintedanibNintedanib esylate 100 mg/1CapsuleOralSandoz Inc0781-249200781-2492-60
nintedanibNintedanib esylate 150 mg/1CapsuleOralSandoz Inc0781-249500781-2495-60

All 18 Nintedanib NDCs

Other NDCs under ANDA 212609

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212609
ProductStrengthForm · routeLabelerProduct NDC
NintedanibNintedanib esylate 100 mg/1CapsuleOralCipla USA Inc.69097-641
Nintedanib Capsules, 100 mg and 150 mgnintedanibNintedanib esylate 100 mg/1CapsuleOralEXELAN PHARMACEUTICALS INC.76282-786
Nintedanib Capsules, 100 mg and 150 mgnintedanibNintedanib esylate 150 mg/1CapsuleOralEXELAN PHARMACEUTICALS INC.76282-787

Free account

Log in to keep searching

You’ve used your 3 free searches. Med-Code is free: log in or create a free profile to keep looking up NDCs, J-codes and drugs.

Create a free profileLog in